Xeris Pharmaceuticals Q4 2025 Earnings Preview
Source: SeekingAlpha
2026-02-27 09:52:29 ET
More on Xeris Pharmaceuticals
- Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
- Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade)
- Xeris Biopharma expects full-year 2025 revenue above estimates
- Seeking Alpha’s Quant Rating on Xeris Pharmaceuticals
- Historical earnings data for Xeris Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Xeris Pharmaceuticals Q4 2025 Earnings Preview
Xeris Pharmaceuticals Inc.
NASDAQ: XERS
XERS Trading
-5.78% G/L:
$5.705 Last:
741,693 Volume:
$5.95 Open:
XERS Latest News
XERS Stock Data
$1,185,529,045
155,188,988
4.48%
76
N/A
Biotechnology & Life Sciences
Healthcare
US
Chicago
